Diagnosis Test for Gestational Diabetes Mellitus

Overview

Gestational diabetes mellitus (GDM) is an asymptomatic disease. Diagnosis is based on a oral glucose tolerance test (OGTT) requiring pregnant women to absorb 75g of glucose while fasting since midnight and to stay sober for another two hours. These OGTTs are poorly tolerated by pregnant women. As many OGTT are false positive according to self-monitoring blood glucose (SMBG), the investigators need now to determine the percentage of OGTT results that are false negative. The comparison of the two tests (OGTT and SMBG) in the same patient with normal results of OGTT will determine the exact percentage of false negative OGTT results. The opinion of women will also be taken into account. In the everyday clinic, many report that they prefer SMBG to OGTT because they do not have to be fasting, to drink non palatable drink and to attend a 2-hour visit in their schedule. However, no opinion study has yet been performed, the investigators will investigate formally what women think using a questionnaire.

Full Title of Study: “Assessment of the Diagnosis Test for Gestational Diabetes Mellitus”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2015

Interventions

  • Procedure: Diagnosis
    • Oral glucose tolerance test and self-monitoring blood glucose

Clinical Trial Outcome Measures

Primary Measures

  • proportion of OGTTs falsely negative
    • Time Frame: Will be evaluated when participants finished SMBG i.e. 7 days after the OGTT

Secondary Measures

  • preference of participants regarding the two tests (OGTT vs. SMBG)
    • Time Frame: Will be evaluated when participants finished SMBG i.e. 7 days after the OGTT
    • Evaluated by questionnaire

Participating in This Clinical Trial

Inclusion Criteria

  • positive GDM screening test (glycemia post-50g of glucose ≥ 7.2 mmol/L), – between 24 and 28 weeks of gestation from the last menstruation, – single pregnancy, – able to read and understand French. Exclusion Criteria:

  • known type 1 or type 2 diabetes, – disease or treatment interfering with the metabolism of glucose, – deficiency may hinder the understanding of the study.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Université de Sherbrooke
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jean-Luc Ardilouze, Endocinologist – Université de Sherbrooke
  • Overall Official(s)
    • Jean-Luc Ardilouze, MD, PhD, Principal Investigator, Université de Sherbrooke

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.